Ulipristal acetate

Ulipristal acetate
Clinical data
Trade names	Ella, EllaOne, Esmya, others
Other names	CDB-2914; 11β-[4-(Dimethylamino)phenyl]-17α-acetoxy-19-norpregna-4,9-diene-3,20-dione
AHFS/Drugs.com	Monograph
License data	US DailyMed: Ulipristal acetate;
Routes of; administration	By mouth
Drug class	Selective progesterone receptor modulator
ATC code	G03AD02 (WHO) G03XB02 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only) / P; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Nearly 100%
Protein binding	96.7–99.5%
Metabolism	Likely CYP3A4
Elimination half-life	32 hours
Excretion	ca. 90% with feces
Identifiers
	IUPAC name [(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;
CAS Number	126784-99-4 ;
PubChem CID	130904;
IUPHAR/BPS	7460;
DrugBank	DB08867 ;
ChemSpider	115762 ;
UNII	YF7V70N02B;
KEGG	D09687;
ChEBI	CHEBI:71025 ;
ChEMBL	ChEMBL260538 ;
CompTox Dashboard (EPA)	DTXSID30155294 ;
ECHA InfoCard	100.207.349
Chemical and physical data
Formula	C30H37NO4
Molar mass	475.629 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)OC4(C(C)=O)CCC3C1CCC2=CC(=O)CCC2=C1C(CC34C)c5ccc(N(C)C)cc5;
	InChI InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1 ; Key:OOLLAFOLCSJHRE-ZHAKMVSLSA-N ;
	(what is this?) (verify)

Ulipristal acetate, sold under the brand name Ella among others, is a medication used for emergency contraception (birth control) and uterine fibroids. As emergency contraception it should be used within 120 hours of vaginally penetrating intercourse. For fibroids it may be taken for up to six months. It is taken by mouth.

Common side effects include headache, nausea, feeling tired, and abdominal pain. It should not be used in women who are already pregnant. It is in the selective progesterone receptor modulator (SPRM) class of medications. It works by preventing the effects of progesterone, therefore preventing ovulation but not affecting fertilization or implantation.

Ulipristal acetate was approved for medical use in the United States in 2010. It is on the World Health Organization's List of Essential Medicines.